Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 4

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 4
---
 Any statement so modified will be deemed to constitute a part of this prospectus only as so modified, and
any statement so superseded will be deemed not to constitute a part of this prospectus. You should read both this prospectus and any applicable
prospectus supplement or post-effective amendment to the registration statement together with the additional information to which we refer
you in the sections of this prospectus titled “Where You Can Find More Information.”

This
prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the
actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some
of the documents referred to herein have been filed or will be filed as exhibits to the registration statement of which this prospectus
is a part, and you may obtain copies of those documents as described below under “Where You Can Find More Information.”

Unless the context specifically
indicates otherwise, references in this prospectus supplement to “Biodexa Pharmaceuticals PLC,” “Biodexa,” “the
Company,” “we,” “our,” “ours,” “us,” “the Group,” or similar terms refer
to Biodexa Pharmaceuticals PLC and its consolidated subsidiaries.

For investors outside the United States: We have not taken any action
to permit a public offering of the Depositary Shares outside the United States or to permit the possession or distribution of this prospectus
outside the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about
and observe any restrictions relating to the offering of the Depositary Shares and the distribution of this prospectus outside of the
United States.

| 1 |

<div align='center'>PRESENTATION OF FINANCIAL AND OTHER INFORMATION</div>

Our
financial statements are prepared in accordance with International Financial Reporting Standards, as issued by the International Accounting
Standards Board. We have made rounding adjustments to some of the figures included in this prospectus. Accordingly, numerical figures
shown as totals in some tables may not be an arithmetic aggregation of the figures that preceded them.

We
prepare our consolidated financial statements in British pounds sterling. Except as otherwise stated, all monetary amounts in this prospectus
are presented in British pounds sterling.

In this prospectus, unless
otherwise specified or the context otherwise requires:

| · | “$” and “U.S. dollar” each refer to the United States dollar (or units thereof); 
 and                                                                              |

| · |